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Modulation of Rho GTPase Signaling Regulates
a Switch between Adipogenesis and Myogenesis
activity results in activation of the Rho effector target,
Rho-kinase, which can phosphorylate the insulin recep-
tor substrate, IRS, thereby preventing its association
Raffaella Sordella, Wei Jiang, Guang-Chao Chen,
Marcello Curto, and Jeffrey Settleman*
Massachusetts General Hospital Cancer Center and
Harvard Medical School with activated insulin/IGF receptors (Sordella et al.,
2002). Thus, increased Rho activity results in downmod-149 13th Street
Charlestown, Massachusetts 02129 ulation of insulin/IGF signaling. Other investigators have
recently reported a similar relationship between Rho
and insulin signaling (Begum et al., 2002).
Interestingly, many of the signaling components of
the insulin/IGF cell size regulatory pathway are also in-Summary
volved in regulating the differentiation of adipocytes and
myocytes from mesenchymal precursors (Rosen andMature adipocytes and myocytes are derived from a
common mesenchymal precursor. While IGF-1 pro- Spiegelman, 2000). In the present study, we demon-
strate that in mice lacking the p190-B RhoGAP, theremotes the differentiation of both cell types, the signal-
ing pathways that specify the distinct cell fates are is a dramatic reduction in adipogenesis, and embryo-
derived cells are defective for adipogenesis but insteadlargely unknown. Here, we show that the Rho GTPase
and its regulator, p190-B RhoGAP, are components tend to undergo myogenic differentiation in culture. We
have delineated a pathway in which the activated IGF-1of a critical switch in the adipogenesis-myogenesis
“decision.” Cells derived from embryos lacking p190-B receptor directs the downmodulation of Rho GTPase
activity by regulating the subcellular distribution ofRhoGAP exhibit excessive Rho activity, are defective
for adipogenesis, but undergo myogenesis in re- p190-B RhoGAP. This leads to increased IGF-1 signaling
to downstream proteins previously implicated in adipo-sponse to IGF-1 exposure. In vitro, activation of Rho-
kinase by Rho inhibits adipogenesis and is required genesis. These observations define a cytoskeleton-inde-
pendent role for Rho in mammalian development andfor myogenesis. The activation state of Rho following
IGF-1 signaling is determined by the tyrosine-phos- suggest that p190-B RhoGAP regulates a Rho-depen-
dent switch in which reduced Rho activity favors adipo-phorylation status of p190-B RhoGAP and its resulting
subcellular relocalization. Moreover, adjusting Rho genesis and increased Rho activity favors myogenesis.
activity is sufficient to alter the differentiation program
of adipocyte and myocyte precursors. Together, these Results
results identify the Rho GTPase as an essential modu-
lator of IGF-1 signals that direct the adipogenesis- Adipocyte Differentiation Is Defective in Mice
myogenesis cell fate decision. Lacking p190-B RhoGAP
We previously generated mice with a targeted disruption
Introduction of the p190-B RhoGAP gene (Sordella et al., 2002). The
mutant mice die at birth and exhibit substantial defects
Members of the evolutionarily conserved Rho family of in insulin/IGF signaling and activation of the CREB tran-
small GTPases are essential regulatory components of scription factor as a result of excessive Rho activity.
signaling pathways that direct the organization of the Since CREB is a major regulator of adipogenesis, we
cytoskeleton (Hall, 1998). Such proteins, which include analyzed potential defects in adipocyte production in
the much-studied Rho, Rac, and Cdc42 GTPases, play newborn mutants using the lipophilic dye, oil-red-O. In
substantial roles in controlling the assembly and organi- wild-type animals, there is prominent staining of subcu-
zation of several actin-based structures, microtubules, taneous fat in dermal tissue sections (Figure 1A),
and cell-cell junctional complexes. Consequently, they whereas in comparable sections from mice lacking
play a prominent role in regulating cell shape, polarity, p190-B RhoGAP (Figure 1B), there is a dramatic reduc-
and movement, as well as in establishing and main- tion in lipid staining, suggesting a defect in adipogen-
taining cell-cell interactions. These biological functions esis. This defect was observed to be completely pene-
of the Rho proteins are critically important in the tissue trant.
morphogenesis events required for the normal develop- To further explore a potential role for Rho and p190-B
ment of multicellular organisms (Settleman, 1999). RhoGAP in adipogenesis, we employed previously de-
We recently reported that disruption of the major Rho veloped methods that allow the efficient conversion of
inhibitory protein p190-B RhoGAP in mice leads to a cultured mouse embryo-derived fibroblasts (MEFs) to
substantial reduction in cell size and animal size as a mature adipocytes through a process that closely reca-
consequence of increased Rho activity (Sordella et al., pitulates the in vivo differentiation of adipocyte precur-
2002). Additional studies revealed that Rho activation is sors (Williams and Polakis, 1977). By treating normal
sufficient to downmodulate insulin/IGF signaling, which MEFs with a “cocktail” of dexamethasone, IBMX (a cAMP
is a well-established key determinant of cell size and agonist), and insulin or IGF-1 for 1 week, a population
animal size in several model systems. Increased Rho of cells emerges that contain readily visible fat droplets
and express several established markers of adipocyte
differentiation.*Correspondence: settleman@helix.mgh.harvard.edu
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Figure 1. p190-B RhoGAP Is Required for Adipogenesis
(A and B) Coronal skin sections from embryonic day (E)18.5 wild-type (A) and p190-B RhoGAP/ mutant (B) embryos stained with oil-red-O
reveals the absence of dermal adipocytes in p190-B RhoGAP/ embryos.
(C and D) Phase-contrast images of wild-type (C) and p190-B RhoGAP/ mutant (D) MEFs following 15 days exposure to the adipogenesis
cocktail (DMIX). The presence of lipid droplets and morphology changes characteristic of adipocytes can be readily detected in the wild-type
cells, but not in the mutants.
(E and F) oil-red-O staining of wild-type (E) and p190-B RhoGAP/ mutant (F) MEFs following 8 days exposure to DMIX reveals a severe
defect in adipogenesis in the mutant cells.
(G) Levels of intracellular triglycerides in cells treated with DMIX for 8 days are substantially reduced in cells lacking p190-B RhoGAP relative
to wild-type MEFs or 3T3-L1 cells. The data represent the mean  the standard error of the mean from three independent experiments.
(H) Immunoblot analysis of PPAR- and C/EBP- expression in wild-type and p190-B RhoGAP/ upon DMIX treatment. Expression differences
are clearly detected after 4 days (4d) of DMIX treatment. -tubulin expression is indicated as a protein normalization control.
MEF cultures from p190-B RhoGAP mutant embryos neither protein is detectably expressed (Figure 1H).
Taken together, these results indicate that p190-B Rho-appear to be significantly impaired in their ability to
undergo adipogenic conversion (Figures 1C–1F). Quan- GAP is required for the differentiation of adipocytes.
tification of triglyceride production in cocktail-treated
wild-type and mutant cells confirmed a reduction in fat
production in mutant cells (Figure 1G). This analysis was Activation of the Rho GTPase Disrupts
Adipogenesis by Blocking IGF-1 Signalingalso performed on 3T3-L1 cells, a preadipocyte mouse
cell line that undergoes adipogenesis with relatively high To identify the signaling pathway affected by the ab-
sence of p190-B RhoGAP, we first compared the abilityefficiency and is used extensively in studies of adipo-
genic differentiation (Williams and Polakis, 1977) (Figure of wild-type and mutant MEFs to differentiate into adipo-
cytes in differentiation medium lacking one or more of1G). By this assay, the degree of adipogenesis detected
in wild-type MEFs is comparable to that seen in 3T3-L1 the cocktail factors. As shown (Figure 2A), IGF-1 appears
to be the major factor that determines adipogenesiscells. To demonstrate that the reduced fat production
in mutant cells reflects decreased adipogenic differenti- in MEFs and is sufficient to induce some degree of
adipogenesis in the absence of IBMX and dexametha-ation as opposed to reduced fat metabolism, we exam-
ined the expression of the adipocyte markers PPAR sone. Significantly, the same relative decrease in differ-
entiation potential is observed in mutant MEFs treatedand C/EBP. In wild-type MEFs exposed to the adipo-
genesis cocktail, expression of these markers is readily with only IGF-1 versus with the complete cocktail, indi-
cating that the adipogenesis defect seen in cells lackingdetected, whereas in MEFs lacking p190-B RhoGAP,
Rho Regulates an Adipogenesis-Myogenesis Decision
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Figure 2. Excessive Rho GTPase Activity
Disrupts Adipogenesis
(A) Defective response to IGF-1 accounts for
the adipogenesis defect in MEFs lacking
p190-B RhoGAP. Relative triglyceride levels
in wild-type and p190-B RhoGAP/ MEFs
after 8 days exposure to the indicated agents.
Note that IGF-1 is sufficient to induce a some-
what efficient adipogenic response and that
this response is defective in the mutant cells.
(B) Adenovirus-mediated expression of a
constitutively active RhoV14 mutant is suffi-
cient to inhibit adipogenesis in wild-type
MEFs (lower left), whereas a GFP-expressing
adenoviral infection has no effect on adipo-
genesis (data not shown). Also, exposure of
the p190-B RhoGAP mutant MEFs to the ROK
inhibitor (Y-27632, 10 M) is sufficient to re-
store normal levels of adipogenesis. Cells
were fixed and stained with oil-red-O after 8
days of treatment with DMIX (lower four pan-
els) or after 8 days in the absence of treatment
(upper two panels).
(C) Relative triglyceride levels in the cells
shown in (B) reveals corresponding effects
of RhoV14 and the Rho-kinase inhibitor. In
addition, note that RhoV14 is sufficient to in-
hibit adipogenesis in 3T3-L1 cells as well.
p190-B RhoGAP reflects largely, if not completely, a seen in wild-type cells (Figures 2B and 2C). This result
indicates that ROK is the Rho target that is relevant todefect in IGF-1 signaling in the mutant cells.
Our previous studies of MEFs lacking p190-B RhoGAP the inhibitory effects of Rho activation on adipogenesis
and that the adipogenesis defect in cells lacking p190-Brevealed that as expected, they contain increased levels
of active Rho-GTP (Sordella et al., 2002). Moreover, we RhoGAP is due to excessive Rho-ROK signaling in these
cells.found that increasing Rho activity in wild-type cells is
sufficient to impair IGF-1 signaling through a mechanism To verify that the adipogenesis defect in MEFs lacking
p190-B RhoGAP reflects decreased signaling throughinvolving an inhibitory phosphorylation on IRS by the
Rho effector target, Rho-kinase (ROK). Therefore, we downstream components of the IGF-1 pathway, we ex-
amined the phosphorylation state of signaling proteinsexamined the ability of activated Rho to affect adipogen-
esis in cultured MEFs expressing the constitutively ac- previously implicated in the adipogenesis process, in-
cluding IRS-1, p38, Akt1, and CREB, upon stimulationtive mutant RhoV14. As shown (Figures 2B and 2C), both
wild-type MEFs and 3T3-L1 cells expressing RhoV14 with IGF-1. Levels of IGF-1 induced phospho-CREB are
decreased by approximately 50% in cells lacking p190-Bexhibit a substantial reduction in adipogenesis.
Significantly, treatment of the mutant MEFs with a RhoGAP (Figure 3A). Similar results were seen with
phospho-Akt and phospho-p38 (data not shown). Ourpharmacological inhibitor of ROK, Y-27632, during dif-
ferentiation restores the level of adipogenesis to that previous studies revealed that in MEFs lacking p190-B
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RhoGAP, the increased activity of Rho, and conse-
quently, ROK, leads to increased phosphorylation of
Ser-612 of the IRS protein, inhibiting its ability to interact
with the IGF-1 receptor (Sordella et al., 2002). Using an
antibody directed against p-IRS (Ser-612), we observed
the expected increase in that phosphorylation in the
mutant cells (Figure 3A).
We confirmed that excessive Rho activity is sufficient
to disrupt these signaling events downstream of IGF-1
by examining the phosphorylation of these signaling
components in IGF-1-treated wild-type cells following
infection with the RhoV14 adenovirus (Figure 3A). More-
over, pretreatment of the mutant cells with the ROK
inhibitor, Y-27632, is sufficient to restore CREB and IRS
phosphorylation to normal levels following IGF-1 treat-
ment. We then determined that the effect of the ROK
inhibitor on CREB phosphorylation is blocked by treat-
ment with a p38MAPK inhibitor but that this agent does
not affect IRS phosphorylation (Figure 3A). These results
indicate that the effect of Rho and ROK on CREB phos-
phorylation is probably due to inhibition of signals down-
stream of the IGF-1 receptor that are mediated by p38
and CREB. Hence, it appears that the increased Rho
activity in mutant MEFs prevents adipogenesis by inhib-
iting signaling downstream of IGF-1.
Rho Activity Is Downmodulated during IGF-Induced
Adipogenesis via p190-B RhoGAP
The observation that excessive Rho signaling inhibits
adipogenesis raised the possibility that Rho activity
must normally be downmodulated during differentiation.
Indeed, we found that levels of Rho-GTP are reduced
considerably within 30 min of IGF-1 treatment, and they
remain low over the course of several days (Figure 3B).
Then, to address a potential role for p190-B RhoGAP in
this process, we compared levels of Rho-GTP in wild-
type and mutant MEFs following IGF-1 treatment. Whereas
Rho-GTP levels are rapidly decreased by IGF-1 in wild-
type cells (as seen in 3T3-L1 cells), Rho-GTP levels actu-
ally increase substantially in the mutant cells following
IGF-1 treatment (Figure 3C). This result suggests that
the active state of Rho following IGF-1 treatment reflects
a balance between opposing activating and inhibitoryFigure 3. p190-B RhoGAP Modulates the Degree of Rho Activation
influences and that in the absence of p190-B RhoGAPupon IGF-1 Treatment
activity, the activating factor is predominant. Thus, the(A) Excessive Rho-ROK signaling in cells lacking p190-B RhoGAP
inhibits IGF-1-induced CREB activation via phosphorylation of IRS. status of p190-B RhoGAP appears to be a key determi-
The inhibitory IRS-Ser-612 phosphorylation is increased in p190-B nant of the degree of Rho activation or inhibition during
mutant cells after 15 min of IGF-1 treatment (80 ngs/ml), as revealed IGF-1-induced differentiation.
by immunoblotting of total cell lysates with a phosphospecific anti-
body. Infection with an adenovirus expressing a constitutive active
p190-B RhoGAP Is Phosphorylated by the Activatedmutant of Rho (RhoV14) 48 hr before IGF-1 stimulation increases the
level of Ser-612 phosphorylation in wild-type MEFs, while pretreatment Insulin Receptor
with the ROK inhibitor (Y-27632, 10 M) blocks phosphorylation. Pre- Since the insulin and IGF receptors are tyrosine kinases,
treatment with the p38 MAPK-specific inhibitor, SB203580 (1 M), we considered the possibility that effects of IGF-1 on
does not affect the level of p-IRS. IGF-1-induced phospho-CREB
Rho GTPase activity are directly mediated by tyrosine(after 15 min) is decreased by approximately 50% in the p190-B
RhoGAP mutant MEFs, as revealed by immunoblotting with a phos-
pho-CREB antibody. After infection of wild-type MEFs with the
RhoV14 adenovirus, IGF-induced CREB phosphorylation is dramati-
come substantially reduced following exposure of 3T3-L1 cells tocally reduced. IGF-induced CREB phosphorylation is rescued in mu-
IGF-1 (80 ngs/ml). Total levels of RhoA are not significantly affected.tant cells by pretreatment with the ROK inhibitor Y-27632. Y-27632
(C) GST-Rhotekin pull-down assays of wild-type and p190-B Rho-pretreatment is not able to rescue IGF-induced CREB phosphoryla-
GAP mutant cell extracts indicating that Rho-GTP levels undergo ation in the presence of the p38 MAPK inhibitor, indicating that the
reduction in wild-type MEFs upon IGF-1 treatment but are markedlypathway through which Rho-ROK activity inhibits CREB phosphory-
increased in p190-B RhoGAP mutant MEFs following IGF-1lation is upstream of p38 MAPK.
treatment.(B) GST-Rhotekin pull-down assay reveals that Rho-GTP levels be-
Rho Regulates an Adipogenesis-Myogenesis Decision
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Figure 4. Ligand-Activated Insulin/IGF Re-
ceptors Directly Phosphorylate p190-B Rho-
GAP on Tyr-306
(A) A peptide containing tyrosine-306 in the
p190-B RhoGAP amino acid sequence
closely matches known sites of phosphoryla-
tion of IRS-1 by insulin and IGF receptor ki-
nases.
(B) Following IGF-1 treatment (15 min, 80 ngs/
ml) of wild-type MEFs, immunoprecipitated
p190-B RhoGAP is found to be tyrosine phos-
phorylated by immunoblotting with an anti-
phosphotyrosine antibody. Lysates from cells
lacking p190-B RhoGAP (/) were included
as a negative control.
(C) In wild-type MEFs, both insulin (100 ngs/
ml) and IGF-1 (80 ngs/ml) promote tyrosine
phosphorylation of p190-B RhoGAP, as re-
vealed by immunoprecipitation with an anti-
phosphotyrosine antibody (PY20), followed
by immunoblotting with a p190-B RhoGAP
antibody. Immunoblotting of FAK (whose ty-
rosine phosphorylation is not detectably
changed by insulin/IGF) in the same PY20
immunoprecipitates served as a normaliza-
tion control.
(D) Purified, recombinant insulin receptor kinase (IRK) directly phosphorylates baculovirus-produced, purified p190-B RhoGAP in an in vitro
kinase assay using 32P-ATP. The reaction products were resolved by SDS-PAGE and subjected to autoradiography.
(E) Immunoprecipitated p190-B RhoGAP from transfected 293 cells is phosphorylated by purified insulin receptor; however, a Y306F mutant
of p190-B RhoGAP is not phosphorylated.
phosphorylation of p190-B RhoGAP. Notably, p190-B lar RhoGAP activity is seen in wild-type or mutant cells
following IGF-1 treatment, indicating that p190-B Rho-RhoGAP has a tyrosine-containing peptide (EEYINL) re-
sembling the reported consensus site for phosphoryla- GAP catalytic activity is not detectably altered by IGF-
1-induced phosphorylation (data not shown).tion by the IGF-1 receptor (Xu et al., 1995), and this
peptide is not conserved in p190-A RhoGAP (Figure 4A). We then considered the possibility that subcellular
redistribution of p190-B RhoGAP in response to IGF-1Therefore, we tested the possibility that p190-B RhoGAP
undergoes tyrosine phosphorylation upon IGF-1 treat- could impact its ability to downmodulate Rho. By frac-
tionating wild-type cells before and after IGF-1 treat-ment. We determined that brief exposure of wild-type
cells to IGF-1 induces tyrosine phosphorylation of p190-B ment, we found that p190-B RhoGAP undergoes a rapid
redistribution upon IGF-1 treatment that results in itsRhoGAP (Figures 4B and 4C). Then, in an in vitro kinase
assay, we found that purified insulin receptor can directly enrichment in a membrane subfraction that contains the
phosphorylate purified p190-B RhoGAP (Figure 4D). lipid rafts (Figure 5A). These cholesterol- and sphingoli-
To test the hypothesis that Tyr-306 is in fact the phos- pid-rich plasma membrane domains have been shown
phorylation site, a Y306F mutation was generated and to be enriched for the presence of the active Rho and
tested. As expected, the Y306F mutated form of p190-B are sites of active insulin and IGF-1 signaling (Lacalle
RhoGAP is expressed but is not detectably phosphory- et al., 2002; Bickel, 2002). The redistribution of p190-B
lated on tyrosine by the purified insulin receptor (Figure RhoGAP to lipid rafts was confirmed by sucrose density
4E). Together, these results suggest that ligand-acti- gradient centrifugation of membranes from IGF-1-stimu-
vated insulin/IGF receptors can directly phosphorylate lated wild-type fibroblasts (Figure 5B). We also deter-
p190-B RhoGAP on Tyr-306. mined that the tyrosine-phosphorylated p190-B Rho-
GAP is present within the lipid raft-enriched membrane
fraction (Figure 5C). Together, these results suggest thatTyrosine-306 Phosphorylation of p190-B RhoGAP
IGF-1 induces the redistribution of p190-B RhoGAP toLeads to Its Subcellular Relocalization
plasma membrane regions where activated Rho local-To address the mechanism by which insulin/IGF-induced
izes, thereby promoting its ability to reduce Rho activity.tyrosine phosphorylation of p190-B RhoGAP influences
We next examined the role of Tyr-306 phosphorylationits function, we first considered the potential regulation
in the subcellular localization of p190-B RhoGAP. Thus,of its catalytic RhoGAP activity. P190-B RhoGAP accounts
wild-type, Y306F, and Y306D (phosphomimicking) formsfor about half of the total RhoGAP activity in fibroblasts
of p190-B RhoGAP were expressed in cells lacking(Vincent and Settleman, 1999). Therefore, we examined
p190-B RhoGAP, and following IGF-1 treatment, celltotal cellular RhoGAP activity in wild-type and p190-B
membranes enriched in lipid rafts were isolated andRhoGAP mutant MEFs before and after treatment with
immunoblotted for p190-B RhoGAP (Figure 5D). As be-IGF-1 to identify potential changes in p190-B’s RhoGAP
fore, wild-type p190-B RhoGAP is readily detected inactivity. Consistent with previous results, MEFs lacking
the lipid raft fraction following IGF-1 treatment. How-p190-B RhoGAP exhibit 40% less total RhoGAP activity
than wild-type MEFs. However, no change in total cellu- ever, the Y306F mutant is not detected in lipid rafts after
Cell
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Figure 5. IGF-1-Induced Phosphorylation of
p190-B RhoGAP Regulates Its Subcellular
Relocalization to Lipid Raft-Enriched Mem-
brane Regions
(A) Wild-type MEFs with and without expo-
sure to IGF-1 (80 ngs/ml) for 5 min underwent
subcellular fractionation and protein fractions
were subjected to SDS-PAGE and immu-
noblotting with the indicated antibodies. Ab-
breviations: tce, total cell extract; cyt, cyto-
sol; mts, membranes Triton-soluble; mti,
membranes Triton-insoluble (glucopyrano-
side-soluble). Note that p190-B RhoGAP is
only detected in the mti fraction following
IGF-1 treatment. RhoA is enriched in the mti
fraction regardless of IGF-1 treatment. Clathrin
was included as a control to demonstrate the
integrity of membrane preparations.
(B) Lipid rafts were prepared from wild-type
3T3 cells with or without 5 min IGF-1 treat-
ment (80 ngs/ml) using sucrose gradient den-
sity centrifugation and immunoblotted with
the indicated antibodies. The “Rafts” fraction
represents the “light” Triton-insoluble mem-
brane material. Note that IGF-1 induces trans-
location of p190-B RhoGAP to this fraction.
Caveolin is a lipid raft marker, and RhoGDI
does not localize to this region. Tce is also
included.
(C) Wild-type MEFs were fractionated to dem-
onstrate that immunoprecipitated p190-B
RhoGAP in the mti fraction is tyrosine phos-
phorylated following IGF-1 treatment (80 ngs/
ml), as revealed by immunoblotting with the
PY20 antibody.
(D) The Tyr-306 phosphorylation of p190-B
RhoGAP is required for its relocalization to
lipid raft enriched membrane fractions follow-
ing IGF-1 treatment. Wild-type 3T3 cells were transiently transfected with expression plasmids corresponding to HA-epitope-tagged wild-
type p190-B RhoGAP or either of two different phosphorylation site mutants: Y306D (phosphomimicking) and Y306F (phosphorylation defective)
were analyzed by SDS-PAGE and immunoblotting with anti-HA antibodies to detect p190-B RhoGAP.
IGF-1 treatment, and the Y306D phosphomimicking (Carnac et al., 1998; Takano et al., 1998). Thus, Rho
appears to perform opposing roles in adipogenesis andform of p190-B RhoGAP is found in this fraction indepen-
dent of IGF-1 treatment. Hence, phosphorylation of myogenesis. Moreover, evidence suggests that SRF
transcriptional activity, which is Rho dependent, medi-p190-B RhoGAP on Tyr-306 following IGF-1 exposure
leads to the relocalization of p190-B RhoGAP to a lipid ates the role of Rho in myogenesis by promoting expres-
sion of several requisite genes, such as MyoD, MEF2,raft-enriched plasma membrane region, where active
GTP bound Rho is localized. and myogenin (Carnac et al., 1998; Marinissen et al.,
2001; Takano et al., 1998). Consistent with this, we found
that levels of SRF-mediated transcriptional activity areMEFs Lacking p190-B RhoGAP Tend to Undergo
Myogenic Differentiation increased in the mutant cells, and this increase is
blocked by inhibiting Rho activity with the Rho-specificWhile analyzing adipogenesis in wild-type and mutant
MEFs, we observed that when MEFs lacking p190-B C3 toxin, indicating that p190-B RhoGAP may affect
myogenesis by antagonizing Rho-dependent SRF tran-RhoGAP are treated with IGF-1 for several days, numer-
ous cells are seen that exhibit a morphology characteris- scriptional activity (data not shown).
tic of myocytes, including an elongated shape (Figures
1D and 6A) and the presence of multiple nuclei (Figure Modulating Rho-ROK Signaling Alters
the Differentiation Program6A). Such cells are never observed in the wild-type MEF
population. The identity of these cells as myocytes was of Adipocyte/Myocyte Precursors
To further explore a role for Rho-ROK signaling in pro-confirmed by immunostaining with an antibody directed
against muscle-specific myosin heavy chain (Figure 6A) moting myogensis, we examined the effects of modulat-
ing this pathway on myogenesis in MEFs. We found thatas well as by immunoblotting of cell lysates with this
antibody and with anti-MyoD (Figure 6B). when wild-type MEFs are treated with DMIX specifically
in the presence of RhoV14, they can undergo myogenicPrevious studies have revealed a role for Rho signaling
in promoting myogenesis. Specifically, levels of Rho- conversion and, additionally, that inhibition of ROK in
mutant MEFs antagonizes myogenesis (Figure 6B).GTP increase during myogenic differentiation (Char-
rasse et al., 2002), and Rho inhibition blocks this process Moreover, when C2C12 cells, a pluripotent mesenchy-
Rho Regulates an Adipogenesis-Myogenesis Decision
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mal cell line that can be readily induced to undergo sion, IGF-1 is a factor that can promote the production
of both cell types. Here, we provide evidence that differ-myogenic differentiation (Bains et al., 1984), are treated
with IGF-1 for several days in the presence of the ROK ential activation of the Rho GTPase in response to IGF-1
provides an important switching function and that theinhibitor, they tend to undergo adipogenesis instead
of myogenesis (Figures 6C and 6D). Together with our phosphorylation status of the Rho regulator p190-B
RhoGAP controls this switch and consequently deter-studies of Rho effects on adipogenesis in 3T3-L1 cells,
these results indicate that modulation of Rho-ROK sig- mines how the cell will respond to the IGF-1 stimulus.
Thus, the regulation of Rho GTPase activity appears tonaling is sufficient to alter the differentiation outcome
of precursors that have the capacity to become either be an important determinant of cell fate in the differentia-
tion of adipocyte and myocyte precursors.adipocytes or myocytes.
Since p190-B RhoGAP is expressed in muscle cells,
we hypothesized that it is regulated differently than it The Role of Rho in Adipogenesis
is in differentiating adipocytes. Indeed, we found that Previous studies revealed that modulation of Rho
during myogenic differentiation of C2C12 cells, the tyro- GTPase activity plays a role in the differentiation of sev-
sine phosphorylation of p190-B RhoGAP steadily de- eral cell types, including neurons (Luo et al., 1996), T
creases and parallels an increase in Rho-GTP levels lymphocytes (Henning et al., 1997), myocytes (Carnac
(Figures 6E and 6F). Significantly, in 3T3-L1 cells under- et al., 1998; Charrasse et al., 2002; Takano et al., 1998),
going adipogenesis, tyrosine phosphorylation of p190-B and keratinocytes (Sugai et al., 1992). Here, we present
RhoGAP steadily increases (Figure 6E). evidence that the inhibition of Rho GTPase activity is
A provocative candidate for a tyrosine phosphatase necessary for the adipogenic differentiation program.
that might dephosphorylate p190-B RhoGAP as a recip- Our conclusion is based on the following observations.
rocal regulatory event during myogenesis is SHP-2. (1) Newborn mice lacking the Rho inhibitory protein
SHP-2 directly regulates components of the insulin sig- p190-B RhoGAP exhibit a nearly complete absence of
naling pathway (Maegawa et al., 1999), it localizes to mature adipocytes. (2) MEFs derived from p190-B Rho-
lipid rafts (Lacalle et al., 2002), it promotes Rho activa- GAP-deficient animals are defective for adipogenesis,
tion (Lacalle et al., 2002; O’Reilly et al., 2000), and it and the defect is rescued by a specific ROK inhibitor.
can promote myogenic differentiation (Kontaridis et al., (3) Introduction of excessive Rho activity into wild-type
2001). During C2C12 differentiation, SHP-2 protein lev- MEFs or 3T3-L1 cells is sufficient to disrupt adipogen-
els steadily increase in parallel with an increase in Rho- esis. (4) Levels of active, GTP bound Rho are normally
GTP levels (Figure 6F), and in coimmunoprecipitations, downregulated during the course of adipogenesis.
we observed that SHP-2 physically associates with Mechanistically, it appears that downmodulation of
p190-B RhoGAP in a tyrosine phosphorylation-depen- Rho during adipogenesis results in relief from an inhibi-
dent manner (Figure 6G). Thus, SHP-2 is likely to play tory phosphorylation of IRS by the Rho effector target
a role in the negative regulation of p190-B RhoGAP ROK and a consequent increase in IGF-1 signaling. We
during muscle differentiation. Taken together, these re- have shown that activation of several downstream com-
sults suggest that the tyrosine phosphorylation status ponents of the insulin/IGF signaling pathway that are
of p190-B RhoGAP provides a regulatory mechanism known to be required for adipogenesis is impaired when
that determines levels of Rho activation in response to Rho activity is excessive and that adipogenesis is dra-
insulin/IGF signaling, thereby serving as a switch in an matically enhanced in the presence of the ROK inhibitor.
adipogenesis-myogenesis “decision.” We also find that phosphorylation of the CREB transcrip-
tion factor, which is sufficient to promote adipogenesis
in 3T3-L1 cells, when activated (Reusch et al., 2000), isDiscussion
very sensitive to the activity of Rho and p190-B RhoGAP
(Sordella et al., 2002).Rho GTPase Activity Regulates an Adipogenesis-
Myogenesis Decision The fact that cultured MEFs derived from the p190-B
RhoGAP mutant animals exhibit a partial defect in adipo-Adipocytes and myocytes are derived from a common
mesenchymal precursor that has the potential to differ- genesis, whereas sections of dermis exhibit an essen-
tially complete loss of adipogenesis, probably reflectsentiate along several distinct lineages. The decision
made by a mesenchymal stem cell to commit to a partic- the context-dependent nature of adipogenic differentia-
tion. It is clear that IGF-1 is not the only extracellularular lineage is highly context dependent and undoubt-
edly involves the integration of multiple extracellular sig- regulator of this process, and studies have implicated
other factors, including TGF-, FGF-10, and macro-nals to drive the outcome. Although relatively little is
known regarding the precise nature of the coordinated phage colony stimulating factor, which are also likely to
contribute to adipogenesis in vivo (Rosen and Spiegel-action of extracellular signals that induce differentiation
of a particular mesenchymal lineage, several factors that man, 2000). It is also possible that the observed differ-
ence is due to the fact that the MEF model of adipogen-can influence the differentiation process have been
identified. These include the cytokines IGF-1, BMP, esis reflects the differentiation of a partially committed
preadipocyte, as opposed to the differentiation of a trulyTGF-, and retinoic acid; the adhesion molecules
N-cadherin, galectin, and several integrins; as well as multipotent mesenchymal stem cell, as would occur in
vivo. In either case, however, our observations that thenumerous downstream transcriptional regulators, such
as CREB, MyoD, PPAR, and MEF2 (Rosen and Spiegel- level of active Rho is normally downmodulated during
adipogenesis and that excessive Rho activity inhibitsman, 2000).
In the context of the adipogenesis-myogenesis deci- adipogenesis in vivo lead to the conclusion that down-
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Figure 6. p190-B RhoGAP Regulates Myocyte Differentiation
(A) Wild-type (/) and p190-B RhoGAP mutant (/) MEFs were exposed to DMIX for 15 days and then fixed and immunostained with an
anti-muscle myosin heavy chain antibody (green). Cells were costained with DAPI (blue) to identify nuclei. Note the presence of multinucleated
myosin-positive cells with a morphology characteristic of myocytes within the population of p190-B RhoGAP mutant cells following DMIX
treatment.
(B) Anti-myosin heavy chain and MyoD immunoblots of wild-type (/) and p190-B RhoGAP mutant (/) MEF lysate following 15 days of
treatment with DMIX, in the presence or absence of RhoV14 or Y-27632 (10 M). Note the expression of muscle-specific markers in MEFs
lacking p190-B RhoGAP and in wild-type MEFs in the presence of RhoV14. The same lysates were immunoblotted with -tubulin antibody
as a control.
(C) C2C12 cells treated for 15 days in the presence of IGF-1 with low-serum medium (untreated) or with low-serum medium plus the ROK
inhibitor (Y-27632) and then stained with anti-myosin heavy chain (upper two panels) to reveal inhibition of muscle differentiation or oil-red-
O (lower two panels) to reveal adipogenesis in cells in which Rho-ROK signaling is disrupted. Green, anti-MHC; Blue, DAPI costain.
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modulation of Rho signaling is essential for the matura- at the time of birth, these animals appear to have normal
musculature, as assessed by gross anatomical exami-tion of adipocytes. Significantly, unlike most previous de-
scriptions of Rho-mediated developmental processes, nation. Thus, p190-B RhoGAP expression does not ap-
pear to be required for the first wave of muscle differenti-the role of Rho in adipogenesis, which we attribute to
ROK activation and subsequent IRS phosphorylation, ation. Notably, mice lacking Trio, a Rho activator, exhibit
a defect in the production of stellate cells that ariseappears to be independent of its ability to affect cy-
toskeletal organization. from the differentiation of mesenchymal cells during the
second wave of myogenesis, indicating a likely role for
Rho in this later stage of muscle differentiation (O’BrienThe Role of Rho in Myogenesis
Accumulating evidence indicates that Rho activity is et al., 2000). However, because our mice die immediately
after birth, it is not possible to determine if p190-B Rho-essential for normal muscle development. Disruption of
Rho signaling by treating muscle cell precursors with GAP activity is required for this second wave of myo-
genesis.the ROK inhibitor, or by expressing either dominant-
negative Rho or the Rho inhibitor RhoGDI, blocks their From our studies, it is clear that phosphorylation of
Tyr-306 is a major regulator of p190-B RhoGAP activity.differentiation (Takano et al., 1998). In addition, Rho-
GTP levels increase steadily during the differentiation When this phosphorylation is present, the protein is
likely to be a more effective Rho inhibitor by virtue ofof C2C12 cells to myoblasts (Charrasse et al., 2002). It
appears that SRF activation by Rho accounts for at least its redistribution to the lipid raft-enriched membrane
regions where active Rho protein is known to accumu-part of its role in promoting myogenesis. However, there
is evidence that Rho promotes muscle differentiation late. Significantly, Tyr-306 is situated within a potentially
exposed loop that spans the third and fourth helices ofthrough additional mechanisms, such as by inducing
phosphorylation of MEF2. Specifically, it has also been the first FF domain of p190-B RhoGAP (Allen et al., 2002).
FF domains are protein interaction domains, and thisproposed that Rho activity increases myocyte differenti-
ation through the activation of PKN, a Rho binding ki- phosphorylation could modify the protein interaction po-
tential of p190-B RhoGAP, consequently affecting itsnase (Marinissen et al., 2001), leading to MEF2 phos-
phorylation, which is required for its transcriptional subcellular redistribution. By comparison with consen-
sus sites of phosphorylation by insulin and IGF-1 recep-activity (Zhao et al., 1999).
The nature of upstream activators of Rho that promote tors present in the IRS protein (Xu et al., 1995), it is
expected that Tyr-306 is a good substrate for both ofmyogenesis is beginning to be elucidated. As described
here, IGF-1 can promote Rho activation in some con- these kinases and might also be a target for other recep-
tor tyrosine kinases.texts, and this may be mediated in part by LARG-Rho-
GEF, a Rho activator that binds the IGF-1 receptor di- To our knowledge, these findings represent the first
description of a signaling pathway that includes a spe-rectly (Taya et al., 2001). Another upstream activator of
myogenic differentiation is N-cadherin, and N-cadherin- cific regulatory phosphorylation of a GAP. While the
biochemical function of GAPs as negative regulators ofmediated cell-cell adhesion contributes to the differenti-
ation of myocytes by promoting Rho-dependent SRF GTPases is well established, relatively little is known
regarding their regulation in vivo or their precise roleactivation (Charrasse et al., 2002). Thus, Rho may medi-
ate multiple signaling inputs that promote myogenic dif- in signal propagation. Many of the known GAPs are
reportedly phosphorylated (Symons and Settleman,ferentiation.
2000), and it is possible that such phosphorylation-medi-
ated regulation of GAP localization is a more widelyp190-B RhoGAP Is a Critical Regulator
of Rho-Dependent Differentiation utilized signaling mechanism.
It appears that Rho is performing opposing functions in
adipogenesis and myogenesis, and our results implicate Context-Dependent Regulation of Cell Fate
by Rho and RhoGAPp190-B RhoGAP as an important regulator of Rho
GTPase activity in the context of the adipogenesis-myo- In light of the role of Rho GTPase activity in the pro-
cesses described above, it is likely that p190-B Rho-genesis decision. MEFs lacking p190-B RhoGAP exhibit
a defect in their capacity to undergo adipogenic differen- GAP’s ability to downmodulate Rho activity accounts
for its role in differentiation. However, since p190-B Rho-tiation, but tend to undergo myogenic differentiation
upon prolonged exposure to IGF-1. While mice lacking GAP appears to be ubiquitously expressed (Burbelo et
al., 1998), we imagine that its stringent regulation inp190-B RhoGAP exhibit a clear defect in adipogenesis
(D) Quantification of adipogenesis in oil-Red-O-stained C2C12 cells from (C) by measuring absorbance of light at 510 nM.
(E) Tyrosine phosphorylation of p190-B RhoGAP is inversely regulated in differentiating myocytes and adipocytes. C2C12 myocyte precursors
(upper two panels) were induced to undergo myogenic differentiation in the presence of IGF-1 (80 ngs/ml), and at the indicated times, cell
lysates were prepared and analyzed by immunoprecipitation with PY20 antibody followed by immunoblotting with anti-p190-B RhoGAP antibody
to detect tyrosine-phosphorylated p190-B RhoGAP. 3T3-L1 adipocyte precursors were similarly analyzed (lower two panels) during the course
of IGF-1-induced adipogenic differentiation. Levels of p190-B RhoGAP in total cell extracts (tce) are also shown.
(F) C2C12 cells were induced to undergo myocyte differentiation, and cell lysates were prepared and analyzed in parallel for expression of
SHP-2, levels of Rho-GTP, and the tyrosine phosphorylation status of p190-B RhoGAP to demonstrate that reduced tyrosine phosphorylation
of p190-B RhoGAP is accompanied by increased levels of SHP-2 and activated Rho.
(G) Cell lysates from wild-type 3T3 cells with or without 10 min exposure to IGF-1 (80 ngs/ml) were analyzed for p190-B tyrosine phosphorylation
and association of p190-B RhoGAP with SHP-2. Note that IGF-1 promotes the association of SHP-2 with p190-B RhoGAP.
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tant mice. Extraction of tail DNA for genotyping, and preparation
and culture of MEFs, including the generation of stable 3T3 cell
lines, were performed as previously described (Brouns et al., 2000).
Induction of Adipocyte Differentiation
3T3-L1 cells and MEFs were induced to differentiate as previously
described (Miki et al., 2001). Briefly, cells were propagated to conflu-
ence, and 2 days later, the medium was replaced with standard
adipocyte differentiation induction medium containing 0.5 mM IBMX,
1 M dexamethasone, 5 g per ml insulin, 10% FBS, 50 U per ml
penicillin, and 50 g per ml streptomycin (differentiation mixture;
DMIX). Medium was replenished every second day for 7-10 days.
Figure 7. Model for the Role of p190-B RhoGAP and the Rho
Oil-Red-O Staining and Triglyceride AssayGTPase in Modulating the Response to IGF-1 in the Context of
Following 7–10 days in differentiation medium, cells were washedAdipogenic and Myogenic Differentiation
with PBS, fixed with 10% formalin for 15 min, then stained withThe tyrosine phosphorylation status of p190-B RhoGAP plays an
0.5% oil-red-O in isopropyl alcohol: distilled water [60:40]) for 30important role in determining the activation state of Rho following
min at 37C, washed with water three times, and air-dried. WhereIGF-1 receptor activation and, consequently, influences the cell fate
indicated, staining was quantified by collecting fixed, stained cellschoice of precursors that have the potential to become either adipo-
in 1 ml of isopropyl alcohol and reading the absorbance of thecytes or myocytes.
solution at 510 nm (peak absorbance for oil-red-O) after dilution to
a linear range. For the triglyceride assay, cells were subjected to
particular cellular contexts provides for its ability to differentiation treatment for 7–10 days in a 24-well plate, washed
with PBS twice, then lysed with 0.8 ml of lysis solution (150 mMfunction as a switch. Two types of signaling inputs ap-
NaCl, 10 mM Tris-HCl [pH 8.0], 0.1% Triton X-100). Triglyceridepear likely to determine the tyrosine phosphorylation
concentration in the filtered homogenate was measured by using Lstatus of p190-B RhoGAP. As we have demonstrated,
type Wako TG-H (S-R1 and S-R2): 125l volume of the homogenate,insulin/IGF-1 signaling can directly promote this phos-
50l of S-R1, and 25l of S-R2 were used. The protein concentration
phorylation via their respective receptor kinases, while of the same homogenate solution was measured with a bicinchoni-
SHP-2 tyrosine phosphatase is as a good candidate for nic acid (BCA) assay kit.
a protein that can cause the inactivation of the phos-
phorylated p190-B RhoGAP. The association of SHP-2 Induction of Myocyte Differentiation
with p190-B RhoGAP, together with the observed in- C2C12 mouse myoblasts were maintained in DMEM supplemented
crease in levels of both Rho-GTP and SHP-2 in differenti- with 15% FBS. To induce differentiation, growth medium was re-
placed with differentiation medium consisting in which the FBSating C2C12 cells, as well as the steady decrease in
concentration was reduced to 2% FBS plus insulin or IGF-1. Cellstyrosine phosphorylation of p190-B RhoGAP during myo-
were observed for 7–10 days for morphological changes. Myogenicgenesis, support a role for inactivation of p190-B Rho-
differentiation of mutant MEFs was achieved by 10–14 days expo-GAP by SHP-2 during myogenesis. Interestingly, previ-
sure to DMIX.
ous studies have revealed that SHP-2 can promote Rho
activation through an unknown mechanism (Lacalle et
Histologic Analysisal., 2002). Our results suggest that SHP-2 activates Rho
E18.5 wild-type and mutant embryos were fixed by immersion (4%
by inactivating p190-B RhoGAP through dephosphory- paraformaldehyde) and then cryoprotected in PBS/20% sucrose.
lation. Coronal cryostat sections (10–14 M) were stained with oil-red-O
Thus, we hypothesize that an extracellular signal pro- for 2 hr. Genomic DNA was prepared from the tail of each animal
prior to fixation, and the genotype was determined by PCR analysis.vided in a particular mesenchymal cell context directs
the increased expression of SHP-2, leading to dephos-
phorylation and inactivation of p190-B RhoGAP and a Immunodetection of Proteins
Cells for immunostaining were grown on 10 mm glass coverslips.consequent increase in Rho and SRF activity. In combi-
Following treatment, cells were fixed in 4% paraformaldehyde innation with an IGF-1 signal, such cells would follow the
PBS (20 min), rinsed in PBS, permeabilized in 0.1% Triton X-100/myogenic lineage (Figure 7). However, in the absence
PBS (1 min), and blocked with 1% normal goat serum (NGS), 0.1%of the signal that induces SHP-2, IGF-1 promotes p190-B
bovine serum albumin (BSA) in PBS (1 hr). Muscle myosin heavy
RhoGAP-mediated Rho inactivation, resulting in adipo- chain antibody was diluted 1:50 in 0.1% BSA/PBS and applied to
genesis (Figure 7). While it is almost certainly true that coverslips for 1 hr. After extensive washing in PBS, primary antibody
additional factors contribute to the differentiation out- was detected with FITC-conjugated donkey anti-goat antibody
(Jackson ImmunoResearch; 1:200 dilution in 0.1% BSA/PBS) in thecome of mesenchymal stem cells, our results point to
presence of DAPI for 1 hr. Where indicated, cells were costainedan important role for Rho GTPase activity. In addition,
with DAPI (0.5 g/ml) by incubation with the secondary antibody.since Rho is a critical regulator of cytoskeletal remodel-
Immunoprecipitations were performed as previously describeding and differentiation of adipocytes and myocytes is
(Sordella et al., 2002), using either 6 g of pY20 (Transduction Labo-
accompanied by substantial morphological change, it ratories) antibodies or 5 l of p190-B antibodies to immunoprecipi-
is tempting to speculate that Rho serves to coordinate tate the respective proteins. Immunoblotting was also performed
changes both in cytoskeletal architecture and gene tran- as previously described (Sordella et al., 2002). Antibodies against
PPAR-, RhoA, -tubulin, MyoD, and mMHC were obtained fromscription that are required for differentiation.
Santa Cruz Biotechnology and used at 1:500 dilution. Antibodies
against p190-B RhoGAP, Caveolin, Clathrin, FAK, and phosphotyro-Experimental Procedures
sine were obtained from Transduction Laboratories and used at
1:1000 dilution. The CREB and pCREB antibodies were obtainedFibroblast Cell Culture Studies
from Cell Signaling and used at 1:1000. The c-EBP antibody wasTo prepare embryo-derived fibroblasts (MEFs), E13.5 embryos were
obtained from timed matings of p190-B RhoGAP heterozygous mu- a gift from Dr. Marie Classon (MGH).
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